alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**EXHIBIT
      32.1**





**CERTIFICATION
      OF CHIEF EXECUTIVE OFFICER**


**PURSUANT
      TO**


**18
      U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO**





SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002





I,
      Gerald
      McIlhargey, President and Chief Executive Officer of St. Joseph, Inc., certify,
      pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002, that this Annual Report on Form 10-KSB of St.
      Joseph, Inc., for the fiscal year ended December 31, 2007, fully complies with
      the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of
      1934 (15 U.S.C. 78m or 78o(d)) and that information contained in this Annual
      Report on Form 10-KSB fairly presents, in all material respects, the financial
      condition and results of operations of St. Joseph, Inc.




Date:
      March 28, 2008





By:
            /s/
                Gerald McIlhargeyName:
                Gerald McIlhargeyTitle:
                President and Chief Executive
                Officer
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Drug Enforcement Administration

                    By Notice dated May 19, 2000, and published in the                     **Federal Register**                     on May 30, 2000, (65 FR 34498), Chemic Laboratories, Inc., 480 Neponset Street, Building 7C, Canton, Massachusetts 02021, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of cocaine (9041), a basic class of controlled substance listed in Schedule II.                

The firm plans to bulk manufacture small quantities of cocaine derivative for a customer.

DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Chemic Laboratories, Inc. to manufacture is consistent with the public interest at this time. DEA has investigated Chemic Laboratories, Inc. to ensure that the company's registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed above is granted.

Dated: August 18, 2000.

John H. King,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 00-26366  Filed 10-12-00; 8:45 am]

BILLING CODE 4410-09-M
#### Marie Kallenberg, Appellant, v Steven Kallenberg, Respondent.

Order unanimously affirmed with costs. Memorandum: Plaintiff appeals from an order which awarded her maintenance pendente lite, and referred her request for in*988terim counsel fees to the trial court. On this record, consisting of conflicting affidavits, we see no reason to substitute our discretion for that of Supreme Court *(see, Stone v Stone,*152 AD2d 560; *Cohen v Cohen,*129 AD2d 550, 551). Appeals from the granting of pendente lite relief are not favored and it is more expedient and economical to proceed promptly to trial *(see, Berger v Berger,*125 AD2d 285). (Appeal from order of Supreme Court, Nassau County, Yachnin, J.—temporary support.) Present—Boomer, J. P., Green, Pine, Balio and Lawton, JJ.
UNPUBLISHED

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 08-7941

UNITED STATES OF AMERICA, Plaintiff - Appellee,

v. JAYLAR TASSMALL BYERS, Defendant - Appellant.

Appeal from the United States District Court for the Western District of North Carolina, at Charlotte. Frank D. Whitney, District Judge. (3:00-cr-00137-FDW-6)

Submitted: May 21, 2009 Decided: May 27, 2009

Before MOTZ, TRAXLER, and AGEE, Circuit Judges.

Affirmed by unpublished per curiam opinion.

Jaylar Tassmall Byers, Appellant Pro Se. Amy E. Ray, Assistant United States Attorney, Asheville, North Carolina, for Appellee.

Unpublished opinions are not binding precedent in this circuit.2 PER CURIAM: Jaylar Tassmall Byers appeals the district court’s order denying his motion for a reduction of sentence pursuant to 18 U.S.C. § 3582(c) (2006). We have reviewed the record and find no reversible error. Accordingly, we affirm on the reasoning of the district court. United States v. Byers , No. 3:00-cr-00137-FDW-6 (W.D.N.C. Sept. 5, 2008). We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

AFFIRMED
Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 1 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 2 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 3 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 4 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 5 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 6 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 7 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 8 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 9 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 10 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 11 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 12 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 13 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 14 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 15 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 16 of 17

Case 5:20-cv-00746-JKP   Document 115   Filed 10/31/22   Page 17 of 17
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5716 Introduced in House (IH)]

112th CONGRESS
  2d Session
                                H. R. 5716

 To establish a Skin Cancer Research Fund to increase funding for the 
conduct or support of research relating to skin cancer by the National 
                         Institutes of Health.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 10, 2012

  Mr. Bilbray (for himself and Mrs. Maloney) introduced the following 
 bill; which was referred to the Committee on Energy and Commerce, and 
  in addition to the Committee on Ways and Means, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 A BILL

 
 To establish a Skin Cancer Research Fund to increase funding for the 
conduct or support of research relating to skin cancer by the National 
                         Institutes of Health.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Melanoma Research Act of 2012''.

SEC. 2. SKIN CANCER RESEARCH FUND.

    (a) Creation of Fund.--There is established in the Treasury of the 
United States a trust fund to be known as the ``Skin Cancer Research 
Fund'', consisting of such amounts as may be deposited into the Skin 
Cancer Research Fund under subsection (b).
    (b) Transfer to Fund of Certain Amounts.--For each of fiscal years 
2013 through 2017, there shall be deposited into the Skin Cancer 
Research Fund amounts equivalent to the taxes received in the Treasury 
during the respective fiscal year under section 5000B of the Internal 
Revenue Code of 1986 (26 U.S.C. 5000B; relating to taxes on indoor 
tanning services).
    (c) Limitation on Availability of Amounts in Fund.--Amounts in the 
Skin Cancer Research Fund shall be available, as provided by 
appropriation Acts, exclusively for the conduct or support of research 
relating to skin cancer by the National Institutes of Health under 
title IV of the Public Health Service Act (42 U.S.C. 281 et seq.).
    (d) Definition.--In this Act, the term ``skin cancer'' means any of 
the following:
            (1) Actinic keratosis.
            (2) Basal cell carcinoma.
            (3) Melanoma.
            (4) Kaposi's sarcoma.
            (5) Squamous cell carcinoma.
                                 <all>
```
IN THE UNITED STATES DISTRICT COURT 

FOR THE WESTERN DISTRICT OF TEXAS 

WACO DIVISION 

NEONODE SMARTPHONE LLC, 

Plaintiff, 

v. 

SAMSUNG ELECTRONICS CO. LTD, and 

SAMSUNG ELECTRONICS AMERICA, 

INC., 

Defendants.

Civil Action No. 6:20-cv-00507-ADA 

JURY TRIAL DEMANDED 

ORDER GRANTING UNOPPOSED MOTION FOR EXTENSION OF TIME TO FILE 

REPLY IN SUPPORT OF MOTION TO DISMISS 

Before the Court is the Unopposed Motion for Extension of Time seeking an extension 

for Defendants to file their Reply In Support of their Motion to Dismiss Plaintiff’s Claims of 

Willful Infringement as to Both Patents-in-Suit and Plaintiff’s Claims of Indirect Infringement 

and Direct Infringement as to U.S. Patent No. 8,812,993 (“Motion to Dismiss”). The Court is of 

the opinion that said motion should be granted. 

It is therefore ORDERED that Defendants’ Unopposed Motion for Extension of Time is 

GRANTED. Defendants will have through November 6, 2020 to file their Reply In Support of 

their Motion to Dismiss Plaintiff’s Claims of Willful Infringement as to Both Patents-in-Suit and 

Plaintiff’s Claims of Indirect Infringement and Direct Infringement as to U.S. Patent No. 

8,812,993. 

IT IS SO ORDERED. 

ENTERED this ____ day of October 2020. 

THE HONORABLE ALAN D ALBRIGHT 

 UNITED STATES DISTRICT JUDGE 

Case 6:20-cv-00507-ADA Document 26-1 Filed 10/26/20 Page 1 of 1
#### TYLER v. STATE.

No. 22672.

Court of Criminal Appeals of Texas.

Dec. 15, 1943.

W. E. Martin, of Abilene, for appellant.

Spurgeon E. Bell, State’s Atty., of Austin, for the State.

GRAVES, Judge.

Appellant was convicted of a violation of the liquor laws of Taylor County. It was also alleged in the pleadings that he had been twice before convicted of like offenses. The jury awarded him a verdict of six months in the county jail, hence this appeal.

The two room house of appellant was searched by Liquor Control Board agents, and concealed in divers places there were found ten pints of whisky, some of it under the bed, some between mattresses, some in the dresser, and some in the kitchen cabinet. While the officers were making the search, appellant, who was not at home at the beginning of the search, drove up to the house in company with a companion, and immediately drove away, but was followed by the officers. The State used two officers alone as witnesses, whose testimony was substantially as above. Appellant’s wife then took the stand in his behalf and testified that she lived with him, and they had six children, the oldest ten years old. That her husband had in the past engaged in selling whisky, but that he had quit, and had been working for the sanitary department of the city of Abilene, and also for Mr. Simpson, who was the companion with him when he drove up at the time of the search. Having a large family, and very meager wages to support them, she, the wife, in order to help support the family, made an arrangement with a Yellow taxicab driver, whose name she did not know, to bring his passengers who desired whisky to her home and she would deliver to them the whisky, and she and the taxicab driver would divide the profits ; that her husband knew nothing about this arrangement, nor did he know the whisky was in the house. It was her whisky. The defense offered no further testimony.

There is but one bill of exceptions in the record and it relates to a remark of the county attorney in his address to the jury. It appears that appellant exercised his right of remaining silent during the taking of testimony in the case and did not take the witness stand. The following remark was made by the county attorney while addressing the jury: “I don’t know how much whisky he had down there; I don’t even know whether the officers found all the whisky he had down there or not; he could tell you.”

This remark is claimed to be a reference to appellant’s failure to testify, and we think such is a direct comment thereon. See Art. 710, C.C.P., and Branch’s Penal Code, p. 209, Sec. 375.

The judgment is reversed and the cause remanded.
Exhibit 10.3
 SECURITIES PURCHASE AGREEMENT
 THIS SECURITIES PURCHASE AGREEMENT Agreement Company Investor Investors)
 PREAMBLE
 Securities Act SEC
 Series F Stock Shares
  
 Definitions
 Affiliate
 Agreement
 Business Day
 Closing Section 2.1
 Closing Date Section 2.1
 Company




---



##### 



Company Counsel
 Common Stock
 Convertible Securities
 Disclosure Materials Section 3.1(e)
 Exchange Act
 FINRA
 Investor
 Lien
 Material Adverse Effect
 Options
 Restricted Shares Section 4.1(a)
 SEC
 SEC Reports Section 3.1(e)
 Series F Stock
 Shares
 Securities Act
 Short Sales Section 3.2(i)
 Trading Day
 -2-




---



##### 



Trading Market
 Transaction Section 3.2(i)
 Transfer Agent
 
 Closing Closing Closing Date
 Closing Deliveries
   
 Representations and Warranties of the Company
 Organization and Qualification
 -3-




---



##### 



Authorization; Enforcement
 No Conflicts Section 3.2
 Issuance of Shares and Common Stock
 -4-




---



##### 



SEC Reports SEC Reports Disclosure Materials
 Capitalization
 Compliance
 -5-




---



##### 



Representations and Warranties of the Investors
 Organization; Authority
 No Public Sale or Distribution provided however
 Investor Status FINRA
 General Solicitation
 -6-




---



##### 



Experience of Such Investor
 Access to Information
 No Governmental Review
 No Conflicts
 -7-




---



##### 



Prohibited Transactions; Confidentiality Transaction Short Sales
 Restricted Securities
 Legends Section 4.1(b) Section 4.1(c)
 No Legal, Tax or Investment Advice
 Offering Documents
 Restrictions on Shares
 -8-




---



##### 



-9-




---



##### 



Transfer Restrictions
 Restricted Shares Restricted Shares provided however
 Requirements for Transfer
 Legend
   Furnishing of Information
 -10-




---



##### 



Integration
 Reservation of Securities
 Treatment of Non-Public Information
 
 Fees and Expenses
 Entire Agreement
 -11-




---



##### 



Notices Section 5.3 Section 5.3
 Amendments; Waivers
 Construction
 Successors and Assigns
 -12-




---



##### 



No Third-Party Beneficiaries
 Governing Law; Venue; Waiver of Jury Trial
 Survival
 Execution
 -13-




---



##### 



Severability
 Replacement of Certificates
  -14-




---



##### 



ALSERES PHARMACEUTICALS, INC.By:
    
    /s/ Kenneth L. Rice Jr.Name: Kenneth L. Rice Jr.Title: EVP & CFOAddress for Notice:239 South StreetHopkinton, MA 01748Tel:
    
    (508) 497-2360Fax:
    
    (508) 497-9964Attn:
    
    Chief Executive OfficerWith a copy to:Wilmer Cutler Pickering Hale and Dorr LLP60 State StreetBoston, Massachusetts 02109Tel
    
    (617) 526-6439Fax:
    
    (617) 526-5000Attn:
    
    Philip Rossetti, Esq.




---



##### 



Investor Signature Page
  Name of Investor:Robert GipsonBy:
    
    /s/ Robert GipsonName:Title:
 Address for Notice:Telephone No.:Facsimile No.:Email Address:Number of Shares: 12,000Aggregate Purchase Price: $300,000
 -2-
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### National Aeronautics and Space Administration

          - [Notice 00-122] 

# AGENCY:

National Aeronautics and Space Administration. 

# ACTION:

Notice of meeting. 

# SUMMARY:

In accordance with the Federal Advisory Committee Act, Public Law 92-463, as amended, the National Aeronautics and Space Administration announces a forthcoming meeting of the NASA Advisory Council, Space Science Advisory Committee. 

# DATES:

Wednesday, November 1, 2000, 8:30 a.m. to 5:30 p.m.; Thursday, November 2, 2000, 8:30 a.m. to 5:30 p.m.; and Friday, November 3, 2000, 8:30 a.m. to Noon. 

# ADDRESSES:

Jet Propulsion Laboratory, 4800 Oak Grove Drive, Building 180, First Floor Conference Room, Pasadena, CA 91109. 

# FOR FURTHER INFORMATION CONTACT:

Dr. Marc Allen, Code S, National Aeronautics and Space Administration, Washington, DC 20546, 202/358-2470. 

# SUPPLEMENTARY INFORMATION:

The meeting will be open to the public up to the capacity of the room. The agenda for the meeting includes the following: 

—Associate Administrator's Program Status Report 

—Science Theme Status Reports 

—Subcommittee Reports 

—GPRA FY 2000 Performance Report Discussion 

—GPRA FY 2002 Performance Plan Status 

—Education and Public Outreach Programs Report 

—Mars Program Reformulation Status 

—Plans for Establishment of a New Fifth NASA Strategic Enterprise 

—Research Division Issues 

It is imperative that the meeting be held on these dates to accommodate the scheduling priorities of the key participants. Visitors will be requested to sign a visitor's register. 

Dated: October 2, 2000.

Beth M. McCormick, 

Advisory Committee Management Officer, National Aeronautics and Space Administration.

[FR Doc. 00-26201 Filed 10-11-00; 8:45 am] 

BILLING CODE 7510-01-P
**UN PUBLISHED** 
UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

**No. 1**  **1 -**  **6 1**  **1 3** 

UNITED STATES OF AMERICA , P laintiff

– Appell ee ,
v. CALVIN LAMONT JACKSON , Defen d a nt

– Appell ant
.

Appeal from the United States District Court for the Distri ct of Sou th Carolina , at Spartanburg
. G. Ross Anderson, Jr. , Senior District Judge. ( 7 : 0 6

- c r - 0 0 7 12

- GRA

- 1; 7:10

- cv - 70300

- GRA )

Submitted : June 2 , 2011 Decided: June 14, 2011

Before MOTZ, GREGORY, and SHEDD , Circuit Judges.

Dismiss ed by unpublis hed per curiam opinion
.
Calvin Lamont Jackson , Appellant Pro Se
. Elizabeth Jean Howard, Assistant United States Attorney, Greenville, South Carolina, for Appellee.
Unpublished opinions are not binding precedent in this circuit.2 PER CURIAM: Calvin La mont Jackson seeks to appeal the district court’s order denying relief on his 28 U.S.C. A. § 2255 ( West Supp. 2010 ) motion. The order is not appealable unless a circuit justice or judge issues a certificate of appealability. 28 U.S.C. § 2253(c)(1) (200 6 ). A certificate of appealability will not issue absent “a substantial showing of the denial of a constitutional right.” 28 U.S.C. § 2253(c)(2) (200 6 ). When the district court denies relief on the merits, a prisoner satisfies this standard by demonstratin g that reasonable jurists would find that the district court’s assessment of the constitutional claims is debatable or wrong. Slack v. McDaniel , 529 U.S. 473, 484 (2000); see Miller

- El v. Cockrell , 537 U.S. 322, 336

- 38 (2003). When the district court den ies relief on procedural grounds, the prisoner must demonstrate both that the dispositive procedural ruling is debatable, and that the motion states a debatable claim of the denial of a constitutional right. Slack , 529 U.S. at 484

- 85. We have independent ly review ed the record and conclude that Jackson has not made the requisite showing. Accordingly, we deny a certificate of appealability and dismiss the appeal. We dispense with oral argument because the facts and legal contentions are adequately present ed in the materials3 before the court and argument would not aid the decisional
process. DISMISSED
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                          57,849
<SECURITIES>                                         0
<RECEIVABLES>                                  254,163
<ALLOWANCES>                                    18,782
<INVENTORY>                                    358,309
<CURRENT-ASSETS>                               681,809
<PP&E>                                       1,147,156
<DEPRECIATION>                                 680,423
<TOTAL-ASSETS>                               1,681,320
<CURRENT-LIABILITIES>                          316,127
<BONDS>                                        571,998
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                        797
<COMMON>                                        11,008
<OTHER-SE>                                     642,641
<TOTAL-LIABILITY-AND-EQUITY>                 1,681,320
<SALES>                                      1,305,717
<TOTAL-REVENUES>                             1,305,717
<CGS>                                        1,047,243
<TOTAL-COSTS>                                1,047,243
<OTHER-EXPENSES>                                 2,609
<LOSS-PROVISION>                                   416
<INTEREST-EXPENSE>                              41,930
<INCOME-PRETAX>                                 31,264
<INCOME-TAX>                                    16,500
<INCOME-CONTINUING>                             14,764
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    14,764
<EPS-BASIC>                                       1.27
<EPS-DILUTED>                                     1.27


</TABLE>